WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced it has successfully regained compliance with The Nasdaq Stock Market LLC’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This ensures the company’s common stock will continue to be listed on the Nasdaq exchange.
The company initially received a notice of non-compliance from Nasdaq on December 4, 2024, after its stock price failed to achieve a closing bid of at least $1.00 for 30 consecutive trading days. To address this, Windtree was required to sustain a minimum closing bid price of $1.00 or higher for at least 10 consecutive trading days.
Windtree achieved this critical milestone on February 21, 2025, marking a turning point in the company’s efforts to maintain its Nasdaq listing. Nasdaq has since confirmed Windtree’s adherence to the requirement and acknowledged the company’s compliance as of late February.
Despite regaining compliance, the company will remain under a mandatory panel monitoring period until March 20, 2026, to ensure continued adherence to Nasdaq’s listing standards.
This development reflects Windtree’s commitment to maintaining its position on the Nasdaq exchange, reinforcing investor confidence and supporting the company’s future growth initiatives.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.